Advisory Board
Steve Glover
Steve Glover
Steve acts the chairman of our Corporate Advisory Board, bringing operational expertise spanning commercialization, integrated product development, and governancem having overseen over 25 product launches in multiple therapeutic areas
Stephen Van Deventer
Stephen Van Deventer
Stephen serves on the Corporate Advisory Board. He brings over 30 years of experience to the role as a Founder and CEO of several companies in the companies in the therapeutics and life sciences sector.
Brian Gallagher, Jr
Brian Gallagher, Jr
Brian will sit on the Corporate Advisory Board, bringing nearly 30 years of critical investment, strategic, and corporate development experience within the Pharma, biotech and life sciences sectors, including raising capital through various channels while at SR One, Abingworth, the Michigan Biomedical Venture Fund, Trekk Venture Partners, and Slate Bio amongst others. He has extensive leadership in venture capital, strategic investments, and corporate development within the biotech and pharmaceutical sectors bringing a wealth of expertise to BioGene. In addition to his investment experience, Brian spent the first dozen years of his career in operational roles within pharmaceutical and biotech startup companies. He holds a PhD in Organic Chemistry from the University of Michigan.
Kathy Rokita
Kathy Rokita
Kathy is joining the Corporate Advisory Board and currently is a Managing Director at CBIZ and has provided consulting services for physician groups and healthcare organizations for over 30 years. She has had successful exits, most notably as a Principal at Somerset CPAs. With a background in treasury management, budgeting and mergers and acquisitions she will provide valuable insight to the company.
Deepak Sampath, PhD
Deepak Sampath, PhD
Deepak serves as chairman or BioGene’s Scientific Advisory Board as well as on BioGene’s Corporate Advisory Board. He has been instrumental in establishing strategic partnerships with academic institutions and industry leaders, a skill that will help moving our science into therapeutic breakthroughs. He has extensive experience in small molecules, protein biologics, nucleic acids and gene therapies and had driven numberas programs from early research and discovery to clinical trials and regulatory approval.
Prof Mirela Delibegovic
Prof Mirela Delibegovic
As a member of BioGene’s Scientific Advisory Board, Mirela brings a wealth of knowledge in metabolic physiology with a focus on diabetes, obesity and CVD. Prof Mirela holds the prestigious Regius Chair of Physiology at The University of Aberdeen, UK.
Barry Ticho, MD, PhD
Barry Ticho, MD, PhD
Barry will serve on BioGene’s Scientific Advisory Board. Barry holds several prestigious roles as Founder and Board Member at Verve Therapeutics, Cardior Pharmaceuticals, Sania Therapeutics and Stoke Therapeutics. He has expertise in advancing groundbreaking treatments across neurology, ophthalmology, cardiovascular, and metabolic diseases, as well as extensive leadership in drug development and biopharma.
Francis Tavares, PhD
Francis Tavares, PhD
Francis sits on the Scientific Advisory Board bringing experience proposing and championing over 15 metabolic targets in several classes in preclinical drug discovery areas encompassing inflammation, cancer, diabetes and immunology.
Kamal Albarazanji
Kamal Albarazanji
Kamal is joining the Scientific Advisory Board. His career spans notable roles at SmithKline Beecham (now GSK) where he contributed to groundbreaking work in renin inhibitors for hypertension, insulin sensitizer like Avandia, and neuropeptide programs for obesity.